Novel Compatibility of Huanglianjiedu Decoction in Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease¹

Su-Ya Ma  
Beijing University of Chinese Medicine

Xu Wang  
Beijing University of Chinese Medicine

Xiang-Yi Du  
Beijing University of Chinese Medicine

Ming-Wan Su  
Beijing University of Chinese Medicine

Xuan Yao  
Beijing University of Chinese Medicine

Jing Shi (✉ shijing872020@163.com)  
Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China

Research

Keywords: Compatibility of traditional Chinese medicine, Behavioral and psychological symptoms of dementia, HuanglianJiedu decoction, Network pharmacology, Molecular docking

DOI: https://doi.org/10.21203/rs.3.rs-124432/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
**Abstract**

**Background:** Alzheimer's disease (AD) is characterized by progressive cognitive decline. Behavioral and psychological symptoms in dementia (BPSD) are another critical characterization of AD besides cognitive deficit. However, the pharmacological treatment of BPSD remains challenging. Huanglian Jiedu decoction (HLJDD), which consists of four herbs, is applied to treat Alzheimer's disease in traditional Chinese medicine, especially AD with BPSD. While the frequently used compatibility of HLJDD, whose principal ingredient is Coptidis Rhizoma (Huang-lian, CR), may not be suitable for treating BPSD. Elucidating the mechanism underlying each herb is critical to HLJDD’s pertinent compatibility.

**Methods:** We utilized network pharmacology to analyze the herbs’ targets and biological processes for treating BPSD in HLJDD and employed molecular docking to explore the binding activity between herbs’ main active ingredients and neurotransmitter receptors.

**Results:** Results showed that Scutellariae Radix (Huang-qin, SR) and Phellodendri Chinensis Cortex (Huang-bai, PCC) have better anti-BPSD effects than CR and Gardeniae Fructus (Zhi-zi, GF). SR has a better anti-neuroinflammation function, can better regulate blood vessels. PCC has a higher binding affinity with Dopamine D2 receptor (DRD2) and 5-hydroxytryptamine receptor 2A (HTR2A). CR and GF may be better for neuronal signaling.

**Conclusion:** For treating BPSD, SR and PCC are the principal ingredients while CR and GF are the ancillary herbs.

**Background**

In traditional Chinese medicine (TCM), herbs combined into a formula to reinforce the overall effects or eliminate the adverse effects [1], which is called the compatibility of TCM. Although formulas generally have conventional compatibility, it is essential to consider novel compatibility with different diseases. In our research, we proposed an innovative method for the compatibility of herbs based on molecular mechanisms. We investigate HLJDD’s novel compatibility in BPSD.

BPSD appears in more than 90% of AD patients, including anxiety, agitation, aggression, irritation, depression, apathy, disinhibition, delusions, or hallucinations [2]. Molecules that involve in BPSD pathogenesis have been researched by mounting studies. Neuroinflammation, a response that involves neurons and microglia, has been reported to characterize many neurodegenerative diseases and neuropsychiatric conditions, resulting in the elevated production of pro-inflammatory cytokines, like IL-6, TNF-α, IL-8, IL-4, etc. Microglia activation is the first sign of neuroinflammation. Activated microglia can release various oxidants such as reactive oxygen species and activate several genes and proteins, such as inducible nitric oxide synthase [3]. Neurotransmitters and their receptors are considered to play a potential role in BPSD [4]. Genetic risk factors offer a powerful approach for the elucidation of mechanisms underlying BPSD. APOE epsilon 4, the most recognized genetic risk factor for late-onset AD, increasing the risk of BPSD [5]. However, the efficacy of antipsychotics for the treatment of BPSD is scanty. Antipsychotic drugs that are often used to treat BPSD have extrapyramidal severe side effects (EPS). Memantine, the NMDA receptor antagonist, a cure for treating moderate-to-severe AD, can reduce the antipsychotic-induced EPS [6] but had a controversial effect in treating BPSD. Acetylcholinesterase inhibitors, the current primary medication for AD, is controversial when treating BPSD [7]. Many researchers turn their attention to natural products as an alternative or complementary method to BPSD for their clinical efficacy with minimal side effects.

BPSD has different TCM syndrome differentiation. "Toxin damaging brain collaterals," an essential differentiation of BPSD, is put forward by academician Yongyan Wang in the study process of dementia. For this syndrome differentiation, the brain collaterals are injured by the toxins of fire. For the treatment, purging fire for removing toxins is commonly used. HLJDD is a classic prescription for heat-clearing away and detoxifying, which is composed of SR (Huang-qin), CR (Huang-lian), PCC (Huang-bai), and Gardeniae Fructus (Zhi-zi). Studies show that HLJDD is frequently applied for Alzheimer's disease [8], especially with BPSD [9]. While the TCM physicians seldom treat BPSD only with HLJDD. Making out the principal herbs is essential to BPSD, for the intrinsic compatibility of HLJDD maybe not suitable. To better understand HLJDD’s compatibility in treating BPSD, we utilized network pharmacology and molecular docking to provide useful drugs for BPSD therapeutics by emphasizing their molecules’ activities.

**Material And Methods**

**Herbs’ main active ingredients and their matched potential target proteins**

A natural plant contains various chemical compounds. Our study used the TCM systems pharmacology database and analysis platform (TCMSP, https://tcmspw.com/index.php) to detect herbs’ main active ingredients. And filtered compounds by terms of oral bioavailability (OB) ≥ 30%, drug-likeness (DL) ≥ 0.18, drug half-life (HL) ≥ 4 h. Then predicted the active ingredients’ potential molecular targets by the search tool for interactions of chemicals database (STITCH, http://stitch.embl.de/) with the species limited to "Homo sapiens."

**Potential targets prediction for behavioral and psychological symptoms of dementia in Alzheimer's disease**

We identified BPSD-associated protein targets by the GeneCards database (http://www.genecards.org/) [10], with a higher rank score, higher correlation with BPSD. The searched keywords were "behavioral and psychological symptoms of dementia in Alzheimer's disease." We chose the top 50% of predicted targets as the potential targets for BPSD.

**Network construction and analysis**

We constructed the "compounds-targets-BPSD" networks by Cytoscape 3.7.2 software [11]. The .csv format files whose data combined compounds targets with BPSD targets were imported into Cytoscape. The node size was based on the target proteins score values provided by the GeneCards database. The
overlapping targets between active compounds and BPSD were the herbs’ putative targets related to BPSD and set with a red rectangle node. Memantine was applied to choose the potential neurotransmitter receptors in this process.

**Annotation enrichment analysis of target proteins**

We performed Gene Ontology (GO) functional enrichment analysis using the ClueGO plugin[12], with the species limited to ‘Homo sapiens’ and p-value < 0.05.

**Molecular docking for active compounds with DRD2 and HTR2A**

Molecular docking studies were conducted using AutoDock software[13] to evaluate the active compounds’ binding affinity with neurotransmitter receptors. The neurotransmitter receptors DRD2 and HTR2A were selected as the docking receptor. The memantine’s mechanism on BPSD determined to choose them. We downloaded the proteins’ crystal structure from the RCSB Protein Data Bank (http://www.rcsb.org/). We chose 6CM4 and 6A93, whose ligand is Risperdal as the crystal structure. Then memantine, Risperdal, and the active compounds were docked with DRD2 and HTR2A. The binding pocket of DRD2 and HTR2A was set up regarding 6CM4 and 6A93.

**Results**

**HLJDD’s main active compounds and potential target proteins**

After searching the TCMSP database, We sifted out 80 compounds in HLJDD. SR, CR, PCC, and GF have 32, 10, 27, and 11 ingredients, respectively. Then import those compounds into the STITCH database to achieve the potential target proteins (Table 1).

**"Compounds-targets-BPSD" network and GO biological process analysis**

In this network, the red rectangular nodes represent herbs’ key protein targets of BPSD were the most in SR, followed by PCC, 24, and 15, respectively. For further research of the herbs’ key protein targets, we applied GO biological process analysis. Fig. 1 b, c, d, and Tab.2 show the biological processes of the key target proteins of SR, include positive regulation of smooth muscle cell proliferation, lipopolysaccharide-mediated signaling pathway, regulation of neuroinflammatory response, etc. Fig. 2 b, c, d, and Tab.3 reveal the biological processes of the key target proteins of CR. Its biological processes are cellular response to cadmium ion, response to nicotine, and negative regulation of macroautophagy. Fig. 3 b, c, d, and Tab.4 illustrate PCC’s key target proteins’ biological processes. Include response to nicotine, glial cell apoptotic process, plasma lipoprotein particle, etc. Fig. 4 b, c, d, and Tab. 5 show the biological processes of the key target proteins of GF, which are mainly associated with regulation of amyloid-beta formation, regulation of membrane protein ectodomain proteolysis and regulation of nitric oxide biosynthetic process.

**"Compounds-targets-BPSD" network of memantine**

Patients with moderate to severe AD exhibit relatively severe cognitive and psychological symptoms. N-Methyl-D-aspartic acid (NMDA) is one of the main treatments. Memantine is the most prevalent choice of NMDA[14]. In our research, we took memantine as a reference drug. We did the “compounds-targets-BPSD” network of memantine to search its potential mechanism on BPSD, especially for the neurotransmitter receptor. The network result showed that DRD2 and HTR2A were the neurotransmitter receptors that worked on BPSD. We chose DRD2 and HTR2A to do molecular docking for their crystal structure to be better docked and studied with Risperdal ligand in the PDB database.

**Results of molecular docking**

Serotonin and its receptors, particularly the HTR2A, are considered to play a potential role in cognitive behaviors and psychiatric conditions such as depression, schizophrenia, and AD[15]. A multitarget-directed ligand, acting on HTR2A and DRD2, exerting an anti-aggressive and antipsychotic activity, posing a promising strategy for the treatment of BPSD[16]. In our study, the active ingredients were selected as the docked compounds with DRD2 and HTR2A. The 3D structures of the active ingredients were downloaded in .mol2 format from the TCMSP database. They were later converted into .pdb format with the Open Babel GUI software[17]. We used the local search parameters and rigid filename of the macromolecule model when docking. We set the software’s default values as our docking parameters. We set grid box size as follows: DRD2: x-dimension: 62, y-dimension: 84, z-dimension: 126, spacing: 0.375, X center: 17.469, y center: 7.307, z center: 2.7. HTR2A: x-dimension: 126, y-dimension: 62, z-dimension: 84, spacing: 0.497, X center: 30.895, y center: 0.518, z center: 63.697. These parameters were minor adjusted during docking.

In our result, beta-sitosterol had the lowest docking energy with DRD2 (-9.58 Kcal/mol) and HTR2A (-8.2 Kcal/mol) than other docked compounds, include memantine and Risperdal. Stigmastrol, chelerythrine, and campesterol also have lower docking energy than memantine and Risperdal. PCC contains most of these compounds. (Tab.6 and Fig. 5).

**Discussion**

TCM plays an essential role in medical diagnosis and treatments. Based on the TCM theory. Chinese formulas contain a mixture of herbs, which combined the following compatibility principle "monarch, minister, assistant, and guide." meaning herbs play a primary, secondary, auxiliary, or harmonic roles, respectively[18]. The primary herbs are substances that provide the main therapeutic thrust. The second primary herbs enhance or assist the therapeutic actions of the first. The rest serve one of the following functions: treat accompanying symptoms, moderate the harshness or toxicity of the primary ones, guide the medicine to the proper organs, or exert a harmonizing effect[19]. In HLJDD, CR acts as the monarch role. SR plays the minister role. PCC and GF were the assistant and guide role. However, this compatibility is not suitable for treating BPSD. Our research studied drugs from the molecular perspective, which provides a novel method for the compatibility of formulas. Our results showed that SR and PCC are the principal herbs, CR and GF are the assistant herbs.
BPSD is a critical neuropsychiatric feature in Alzheimer's disease [4]. In Alzheimer's disease, abnormal accumulation of amyloid-β released from amyloid precursor protein and neuroinflammation are the partially pathologic hallmarks. Accumulation of amyloid-β also causes indirect injury to neurons by inducing neuroinflammation [20]. Microglia, the resident innate immune cells in the brain, is pivotal for the immune response observed in AD, acting as sentinel and protective cells, but may become inappropriately reactive in AD to drive neuropathology [21]. Lipopolysaccharide (LPS) is a gram-negative bacterial endotoxin released from the cell wall component that contributes to inflammation in the body. LPS is involved in the regulation of the expression of potent inflammatory factors [22]. Studies showed that with age, microglia exhibit enhanced sensitivity to inflammatory stimuli, similar to that observed in brains with ongoing neurodegeneration [23]. An increasing number of data has linked schizophrenia with neuroinflammatory conditions and microglia, which have been related to the pathogenesis of schizophrenia. Evidence suggests that neuroinflammatory changes observed in schizophrenia involve abnormal astrocyte functions [24].

In our research, Scutellaria baicalensis has anti-inflammatory roles in the schizophrenia. A wide range of diseases is associated with dysregulation of macroautophagy. Macroautophagy has a critical role in cellular homeostasis. Either insufficient or excessive macroautophagy can seriously compromise cell physiology, and thus, it needs to be regulated appropriately [30]. CR can negatively regulate macroautophagy. PCC can regulate the glial cell apoptotic process.

Research showed that Nicotine might be involved in the pathophysiology of psychosis. Smoking has a relationship with depression. In animal models, Nicotine shows anxiolytic properties. Depression people are more likely to smoke and more likely to develop severe depressive episodes upon smoking cessation. Nicotine has also been observed to produce similar cognitive improvements in AD patients [31]. However, the relationship between smoking and AD is still debatable [32]. In our herbs, CR, PCC has the function to respond to Nicotine.

It has been demonstrated that serotoninergic, dopaminergic, and cholinergic systems are mainly involved in the pathogenesis of BPSD, and the role of HTR2A and DRD2 as therapeutic targets appear to be evident [14]. Our research utilized molecular docking to find potential active ingredients with good binding activities to DRD2 and HTR2A. The best-ordered compound was beta-sitosterol. The free binding energy of beta-sitosterol with DRD2 and HTR2A was ~9.58 kcal/mol, -8.2 kcal/mol, respectively. Stigmasterol, chelerythrine, and campesterol also have good binding activities. Beta-sitosterol, Stigmasterol, chelerythrine, and campesterol are the active ingredients of PCC. It is the only herb containing these five ingredients.

The TCM theory verifies our results. Triple energizers mean upper, middle, and lower energizer in TCM theory. They are the birth and channel to run for Qi, blood, thin, thick fluids, and essence. Moreover, they also contact five Zang-organs and six Fu-organs. SR affects the upper energizer, which is the brain and heart. PCC works on the lower energizer that is the kidney and liver. CR influences the middle energizer that consists of the spleen and stomach. Kidney essence deficiency is a primary syndrome differentiation of AD in TCM theory. ‘Liver fire’ is the largest contributor to BPSD due to the imbalance between yin and yang of liver function [33, 34]. PCC acts on the lower energizer can purge the liver fire. ‘Su Wen’ puts forward that “the mind is the monarch's official, and the gods come out of it.” In the compendium of Materia Medica, Shizhen Li of the Ming Dynasty proposed that “the brain is the house of primordial God.” SR works on the heart and brain, belongs to the upper energizer, is beneficial for the heart and brain. In conclusion, SR and PCC are HLJDD’s primary herbs based on the TCM theory.

**Conclusions**

The therapeutic value of natural products in BPSD has increased in reputation due to their clinical impact and insignificant side effects. Recently, different types of compounds were reviewed for their biological activities. In this review, we summarize the natural products of HLJDD for the molecules' targets and biological processes involved in the treatments of BPSD. Furthermore, put forward novel compatibility of HLJDD to BPSD. Our results showed that SR has more molecule targets and biological processes involved in BPSD, PCC contains more good-docked compounds: poriferast-5-en-3beta-ol (beta-sitosterol), Stigmasterol, chelerythrine, and campesterol, which have lower affinity energy with DRD2 and HTR2A. SR and PCC are the primary drugs in treating BPSD. SR plays an anti-inflammatory role; PCC can regulate the apoptotic process and respond to nicotine. All of them can regulate blood vessels. CR and GF play the assistant role in BPSD. They have a better position on neuronal signaling.

**Abbreviations**
AD Alzheimer's disease; BPSD: Behavioral and psychological symptoms in dementia; HLJDD: Huanglian Jiedu decoction; CR: Coptidis Rhizoma (Huang-lian); SR: Scutellariae Radix (Huang-qin); PCC: Phellodendri Chinensis Cortex (Huang-bai); GF: Gardeniae Fructus (Zhi-zi); DRD2: Dopamine D2 receptor; HTR2A: 5-hydroxytryptamine receptor 2A; TCM: traditional Chinese medicine; EPS: extrapyramidal severe side effects; TCMSP: TCM systems pharmacology database and analysis platform; OB: oral bioavailability; DL: drug likeness; HL: half-life; STITCH: search tool for interactions of chemicals database; GO: Gene Ontology; D-CS: BPSD correlation score; NMDA: N-Methyl-D-aspartic acid; LPS: Lipopolysaccharide; NO: nitric oxide.

Declarations

Acknowledgements

Not applicable.

Authors' contributions

SM, XW, and XD conceived and designed the study. SM, XW, and MS constructed the pharmacology networks. SM, XD, and XY performed molecular docking analysis. SM wrote the manuscript. XW and XD edited pictures. JS revised the manuscript. All authors were responsible for reviewing data. All authors read and approved the final manuscript.

Funding

This work was supported by the Program for Changjiang Scholars and Innovative Research Team in University (No: IRT0810) and Innovative Research Team of Beijing University of Chinese Medicine (No: 2019-JYB-TD-007).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing financial interest.

Author details

1 Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.

References

1. Zhang N, Li L, Wang P, et al. Pharmacokinetics of the main compounds absorbed into blood after oral administration of Liu Wei Di Huang Wan, a typical combinational intervention of Chinese medical formula. J Nat Med. 2013;67:36-41. doi: 10.1007/s11418-012-0641-3.

2. Chakraborty S, Lennon JC, Malkaram SA, et al. Serotonergic system, cognition, and BPSD in Alzheimer's disease. Neurosci Lett. 2019;704:36-44. doi: 10.1016/j.neulet.2019.03.050.

3. Eissa N, Sadeq A, Sasse A, et al. Role of Neuroinflammation in Autism Spectrum Disorder and the Emergence of Brain Histaminergic System. Lessons Also for BPSD? Front Pharmacol. 2020;11:886. doi: 10.3389/fphar.2020.00886.

4. Tang L, Wang Y, Chen Y, et al. The Association between 5HT2A T102C and Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease: A Meta-Analysis. Biomed Res Int. 2017;2017:5320135. doi: 10.1155/2017/5320135.

5. Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta LA, et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry. 2008;13:772-85. doi: 10.1038/sj.mp.4002088.

6. M B, E P. The role of Serotonin Receptors in Alzheimer's disease. Opera Medica & Physiologica:89-98.

7. Lin CH, Lane HY. The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia. Front Pharmacol. 2019;10:540. doi: 10.3389/fphar.2019.00540.

8. Chen Y, Xian Y, Lai Z, et al. Anti-inflammatory and anti-allergic effects and underlying mechanisms of Huang-Lian-Jie-Du extract: Implication for atopic dermatitis treatment. J Ethnopharmacol. 2016;185:41-52. doi: 10.1016/j.jep.2016.03.028.

9. Shi J, Ni J, Tian J, et al. A systematic review on heat-clearing and toxicity-removing therapy for Alzheimer's disease. Bei Jing Zhong Yi Yao Da Xue Xue Bao. 2019;42:667-72.
10. Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016;54:1-30. doi: 10.1002/cpbi.5.
11. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498-504. doi: 10.1101/gr.1239303.
12. Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091-3. doi: 10.1093/bioinformatics/btp101.
13. Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model. 1999;17:57-61.
14. Chen R, Chan PT, Chu H, et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. Plos One. 2017;12:e183586. doi: 10.1371/journal.pone.0183586.
15. Tang L, Wang Y, Chen Y, et al. The Association between 5HT2A T102C and Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease: A Meta-Analysis. Biomed Res Int. 2017;2017:5320135. doi: 10.1155/2017/5320135.
16. Bucki A, Marcincikowa M, Sniecikowska J, et al. Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). Eur J Med Chem. 2020;191:112149. doi: 10.1016/j.ejmech.2020.112149.
17. O’Boyle NM, Banck M, James CA, et al. Open Babel: An open chemical toolbox. J Cheminform. 2011;3:33. doi: 10.1186/1758-2946-3-33.
18. Ma L, Zhang X, Xu X, et al. Compatibility principle in the Tanyu Tongzhi Formula revealed by a cell-based analysis. J Ethnopharmacol. 2019;231:507-15. doi: 10.1016/j.jep.2018.11.043.
19. Yuan R, Lin Y. Traditional Chinese medicine: an approach to scientific proof and clinical validation. Pharmacol Ther. 2000;86:191-8. doi: 10.1016/s0163-7258(00)00039-5.
20. Fujikawa R, Higuchi S, Nakatsuji M, et al. Deficiency in EP4 Receptor-Associated Protein Ameliorates Abnormal Anxiety-Like Behavior and Brain Inflammation in a Mouse Model of Alzheimer Disease. Am J Pathol. 2017;187:1848-54. doi: 10.1016/j.ajpath.2017.04.010.
21. Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, et al. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Curr Opin Neurobiol. 2016;36:74-81. doi: 10.1016/j.conb.2015.10.004.
22. Guo L, Zhang H, Li W, et al. N-acetyl cysteine inhibits lipopolysaccharide-mediated induction of interleukin-6 synthesis in MC3T3-E1 cells through the NF-kB signaling pathway. Arch Oral Biol. 2018;93:149-54. doi: 10.1016/j.archoralbio.2018.06.007.
23. Yin F, Sancheti H, Patil I, et al. Energy metabolism and inflammation in brain aging and Alzheimer's disease. Free Radiol Biol Med. 2016;100:108-22. doi: 10.1016/j.freeradbiomed.2016.04.200.
24. Gomes FV, Lorente R, Del BE, et al. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr Res. 2015;164:155-63. doi: 10.1016/j.schres.2015.01.015.
25. Baumer Y, McCurdy S, Alcala M, et al. CD98 regulates vascular smooth muscle cell proliferation in atherosclerosis. Atherosclerosis. 2017;256:105-14. doi: 10.1016/j.atherosclerosis.2016.11.017.
26. Sweeney MD, Kisler K, Montagne A, et al. The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2018;21:1318-31. doi: 10.1038/s41593-018-0234-x.
27. Zhou Y, Yasumoto A, Lei C, et al. Intelligent classification of platelet aggregates by agonist type. Elife. 2020;9. doi: 10.7554/elife.52938.
28. Tejero J, Shiva S, Gladwin MT. Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation. Physiol Rev. 2019;99:311-79. doi: 10.1152/physrev.00036.2017.
29. Forcella M, Lau P, Oldani M, et al. Neuronal specific and non-specific responses to cadmium possibly involved in neurodegeneration: A toxicogenomics study in a human neuronal cell model. Neurotoxicology. 2020;76:168-73. doi: 10.1016/j.neuro.2019.11.002.
30. Wen X, Klionsky DJ. An overview of macroautophagy in yeast. J Mol Biol. 2016;428:1681-99. doi: 10.1016/j.jmb.2016.02.021.
31. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol. 2000;61:75-111. doi: 10.1016/s0301-0082(99)00045-3.
32. Teaktong T, Graham AJ, Johnson M, et al. Selective changes in nicotinic acetylcholine receptor subtypes related to tobacco smoking: an immunohistochemical study. Neuropathol Appl Neurobiol. 2004;30:243-54. doi: 10.1046/j.0305-1846.2003.00528.x.
33. Tian J, Shi J, Wei M, et al. Chinese herbal medicine Qinggongshoutao for the treatment of amnestic mild cognitive impairment: A 52-week randomized controlled trial. Alzheimers Dement (N Y). 2019;5:441-9. doi: 10.1016/j.trci.2019.03.001.
34. Shi J, Wei M, Ni J, et al. Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial. J Transl Med. 2020;18:76. doi: 10.1186/s12967-020-02232-z.

Tables
Table1 HLJDD’s active compounds and potential molecular target proteins
| Herbs      | Active ingredients      | Potential target proteins                                                                 |
|------------|-------------------------|------------------------------------------------------------------------------------------|
| SR         | acacetin                | IL13\|CYP1A2\|VEGFA\|JUN\|STAT1\|NR1I2\|SELE\|CYP1A1\|IL5\|CYP1B1 |
| SR         | wogonin                 | MMP9\|MYC\|HMGB1\|MCL1\|PTGS2\|CDK4\|GATA1\|CNK10\|PLSCR1\|CC2L |
| SR         | baicalein               | MAPK1\|ALOX15\|CDK4\|MMP2\|PLAU\|CYP1A2\|AKT1\|CYP3A4\|ALOX12\|MMP9 |
| SR         | oroxylin a              | MAPK3\|BDNF\|HK2\|SIRT3\|CASP8\|PPIF\|IL6\|SOD2\|PARP1\|NOS1 |
| SR         | Pan Colinin skullcap flavone | CASP3                                                                                     |
| SR         | beta-sitosterol         | DHCR24\|CASP3\|ABCG5\|SREBF2\|ICAM1\|ABC58\|CYP7A1\|SREBF1\|APOE\|ABCB11 |
| SR         | Stigmasterol            | TNF\|IL8\|ABC1\|ABC58\|NR1H2\|SREBF2\|ABC58\|NR1H3\|IL10\|SLCO1B1 |
| SR         | coptisine               | PAWR\|XP01\|TNFSF11\|ESF1                                                                 |
| CR         | quercetin               | MCL1\|ATP5B\|CYP1A1\|HIBCH\|HCK\|STK17B\|SLC2A2\|CYP1B1\|CYP2C8\|PIM1 |
| CR         | berberine               | CCND1\|CASP3\|DPP4\|TP53\|AKT1\|MAPK1\|HMOX1\|LDLR\|PCSK9\|ATP5G2 |
| CR         | coptisine               | PAWR\|TNFSF11\|ESF1\|XP01                                                                 |
| PCC        | berberine               | PCSK9\|ATP5G2\|HMOX1\|MAPK1\|TP53\|CASP3\|AKT1\|DPP4\|LDLR\|CCN1 |
| PCC        | coptisine               | PAWR\|XP01\|ESF1\|TNFSF11                                                                 |
| PCC        | rutaecarpine            | CYP1A1\|TNF\|CYP1A2                                                                 |
| PCC        | Chelerythrine           | GAPDH\|PRKCE\|PLA2G1B\|F2\|CFTR\|CHI3L2\|SLEP\|PLA2G2A\|CORT\|ABCB11 |
| PCC        | Stigmasterol            | IL10\|TNF\|SREBF2\|IL8\|SLCO1B1\|ABC58\|ABC58\|NR1H2\|NR1H3\|ABCA1 |
| PCC        | beta-sitosterol         | ABC58\|SREBF2\|DHR24\|CYP7A1\|ABCB11\|CASP3\|ICAM1\|SREBF1\|ABC58\|APOE |
| PCC        | Fumarine\protopine\    | HRH1\|F2\|KIAA0101                                                                 |
| PCC        | quercetin               | CYP1B1\|STK17B\|PI3M1\|SLC2A2\|CYP1A1\|HCK\|ATP5B\|HIBCH\|CYP2C8\|MCL1 |
| PCC        | poriferast-5-en-3beta-ol| CASP9\|NR1H2\|PARP1\|CASP3\|ABC58\|ABC58\|ICAM1 |
| PCC        | campesterol             | HSD3B2\|ABC58\|ABC58\|CYP7A1\|DHR24\|CSN1S1\|NR1H2 |
| GF         | Sudan III               | CELA1\|CELA3B                                                                 |
| GF         | quercetin               | CYP1B1\|SLC2A2\|STK17B\|CYP2C8\|HCK\|CYP1A1\|MCL1\|PI3M1\|HIBCH\|ATP5B\|ATP5F1B |
| GF         | beta-sitosterol         | SREBF1\|CYP7A1\|ABCB11\|CASP3\|ABC58\|APOE\|ABC58\|SREBF2\|DHR24\|ICAM1 |
| GF         | kaempferol              | UGT1A9\|UGT1A8\|UGT3A1\|UGT1A7\|CYP1B1\|CDK1\|AHR\|UGT1A3\|NR1I2\|RPS6KA3 |
| GF         | Stigmasterol            | ABC58\|IL8\|TNF\|NR1H2\|NR1H3\|SREBF2\|SLCO1B1\|ABC58\|ABCA1\|IL10 |

Table 2 The biological function of SR involved in BPSD
| Function | Groups | Group Genes |
|----------|--------|-------------|
| positive regulation of smooth muscle cell proliferation | Group15 | AKT1|APOE|BDNF|CASP3|CCL2|HMGB1|ICAM1|IL10|IL13|IL6|JUN|MAPK1|MAPK3|MMP9|MYC|PTGS2|SOD2|STAT1|TNF|
| lipopolysaccharide-mediated signaling pathway | Group14 | AKT1|CCL2|ICAM1|IL10|IL13|IL6|JUN|MAPK1|MAPK3|MMP9|MYC|PTGS2|SOD2|TNF|TNFSF11 |
| regulation of neuroinflammatory response | Group13 | AKT1|CASP3|HMGB1|IL10|IL6|MAPK1|MMP9|PTGS2|SOD2|TNF|VEGFA |
| regulation of nitric oxide biosynthetic process | Group12 | AKT1|HMGB1|ICAM1|IL10|IL13|MAPK1|MAPK3|PTGS2|TNF|VEGFA |
| positive regulation of endothelial cell proliferation | Group11 | AKT1|CASP3|HMGB1|ICAM1|IL10|IL6|JUN|MMP9|PTGS2|VEGFA |
| regulation of smooth muscle cell proliferation | Group10 | AKT1|IL10|IL13|IL6|JUN|MMP9|MYC|PTGS2|SOD2|STAT1|TNF |
| positive regulation of nucleotide biosynthetic process | Group09 | MYC|NOS1|PTGS2 |
| positive chemotaxis | Group08 | AKT1|CASP3|HMGB1|IL6|PTGS2|TNF|VEGFA |
| negative regulation of epithelial cell differentiation | Group07 | ICAM1|IL13|MMP9|MYC|STAT1|VEGFA |
| regulation of endothelial cell proliferation | Group06 | AKT1|APOE|CCL2|HMGB1|IL10|JUN|PTGS2|STAT1|TNF|VEGFA |
| negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | Group05 | AKT1|HMGB1|IL6|MMP9|PTGS2|TNF|VEGFA |
| positive regulation of blood vessel endothelial cell migration | Group04 | AKT1|CASP3|HMGB1|IL6|PTGS2|VEGFA |
| cellular response to interleukin-6 | Group03 | ICAM1|IL6|STAT1 |
| vasodilation | Group02 | APOE|NOS1|SOD2 |
| regulation of DNA-templated transcription, initiation | Group01 | CCL2|HMGB1|JUN |
| regulation of interferon-alpha production | Group00 | HMGB1|IL10|STAT1 |

**Table 3** The biological function of CR on BPSD

| Function | Groups | Group Genes |
|----------|--------|-------------|
| cellular response to cadmium ion | Group2 | AKT1|HMOX1|MAPK1 |
| response to nicotine | Group1 | CASP3|HMOX1|MAPK1 |
| negative regulation of macroautophagy | Group0 | AKT1|HMOX1|TP53 |

**Table 4** The biological function of PCC on BPSD
**Table 5** The biological function of GF on BPSD

| Function                                               | Groups | Group Genes                                                                 |
|--------------------------------------------------------|--------|-----------------------------------------------------------------------------|
| response to nicotine                                   | Group4 | AKT1|APOE|CASP3|CASP9|HMOX1|ICAM1|IL10|MAPK1|SELP|TNF|TP53 |
| glial cell apoptotic process                           | Group3 | AKT1|APOE|CASP3|CASP9|HMOX1|TNF|TP53 |
| plasma lipoprotein particle clearance                  | Group2 | APOE|HMOX1|LDLR |
| regulation of platelet activation                      | Group1 | APOE|F2|SELP |
| positive regulation of anion transport                 | Group0 | APOE|CFTR|TNFSF11 |

**Table 6** The docking results of the active ingredients with DRD2 and HTR2A

| Name          | DRD2 (PDB ID:6CM4) binding energy (Kcal/mol) | HTR2A (PDB ID:6A93) binding energy (Kcal/mol) |
|---------------|-----------------------------------------------|-------------------------------------------------|
| memantine     | -6.72                                         | -6.02                                           |
| Risperdal     | -7.71                                         | -7.9                                            |
| beta-sitosterol| -9.58                                         | -8.2                                            |
| stigmasterol  | -9.17                                         | -8.9                                            |
| chelerythrine | -8.1                                          | -8.12                                           |
| campesterol   | -7.37                                         | -8.67                                           |
| berberine     | -7.87                                         | -7.61                                           |
| Oroxylin a    | -7.38                                         | -6.42                                           |
| acacetin      | -7.31                                         | -5.8                                            |
| Sudan III     | -6.87                                         | -6.95                                           |
| baicalein     | -6.7                                          | -6.0                                            |
| kaempferol    | -6.33                                         | -5.49                                           |
| wogonon       | -5.68                                         | -5.95                                           |
| quercetin     | -5.82                                         | -5.04                                           |
| panicllin     | -5.53                                         | -5.74                                           |
| coptisine     | -                                             | -                                               |
| rutaecarpine  | -                                             | -                                               |
| fumarine      | -                                             | -                                               |

Note: "-" indicates that the result has not been calculated.

**Figures**
Figure 1

Schematic representation of SR's potential mechanism in treating BPSD. a The “compounds-targets-BPSD” network of SR. This systematic approach successfully revealed 24 key protein targets related to BPSD: APOE ((BPSD correlation score, D-CS): 156.68), TNF (D-CS: 114.77), SOD2 (D-CS: 114.23), IL 6 (D-CS: 105.12), BDNF (D-CS: 104.54), IL 10 (D-CS: 86.21), VEGFA (D-CS: 72.66), AKT1 (D-CS: 66.45), CCL2 (D-CS: 66.37), MAPK1 (D-CS: 52.1), PLAU (D-CS: 41.02), CASP3 (D-CS: 37.17), ICAM1 (D-CS: 37.08), PTGS2 (D-CS: 35.32), NOS1 (D-CS: 32.33), MMP9 (D-CS: 30.39), MYC (D-CS: 30.15), IL 13 (D-CS: 29.05), MAPK 3 (D-CS: 26.17), HMGB 1 (D-CS: 23.14), JUN (D-CS: 22.83), STAT1 (D-CS: 20.14), TNFSF 11 (D-CS: 18.98), CYP3A4 (D-CS: 17.31). b, c, d GO biological processes analysis of SR. SR's key protein targets involved 156 biological processes, like positive regulation of smooth muscle cell proliferation, lipopolysaccharide-mediated signaling pathway, and neuroinflammatory response.
Figure 2

Schematic representation of CR's potential mechanism in treating BPSD. a The "compounds-targets-BPSD" network of CR. It revealed that seven key protein targets were related to BPSD: TP53 (D-CS: 72.85), AKT 1 (D-CS: 66.45), HMOX 1 (D-CS: 50.08), LDLR (D-CS: 40.09), MAPK 1 (D-CS: 52.1), CASP 3 (D-CS: 37.17), TNFSF 11 (D-CS: 18.98). b, c, d GO biological processes analysis of CR. The key protein targets of CR involved three biological processes: they are negative regulation of macroautophagy, response to nicotine, and cellular response to cadmium ion.
Figure 3

Schematic representation of PCC’s potential mechanism of BPSD. a The “compounds-targets-BPSD” network of PCC. It revealed that 15 key protein targets were involved in BPSD: APOE (D-CS: 156.68), TNF (D-CS: 114.77), IL 10 (D-CS: 86.21), TP 53 (D-CS: 72.85), AKT 1 (D-CS: 66.45), MAPK 1 (D-CS: 52.1), HMOX 1 (D-CS: 50.08), LDLR (D-CS: 40.09), F 2 (D-CS: 38.83), CASP 3 (D-CS: 37.17), ICAM 1 (D-CS: 37.08), PLA2G2A (D-CS: 33.98), CFTR (D-CS: 21.04), CASP 9 (D-CS: 20.76), TNFSF 11 (D-CS: 18.98), SELP (D-CS: 17.65). b, c, d GO biological process analysis of PCC. PCC’s key protein targets involved 35 biological processes like a response to nicotine, glial cell apoptotic process, and positive regulation of anion transport.
Figure 4

Schematic representation of GF’s potential mechanism involved in BPSD. a The “compounds-targets-BPSD” network of GF. It revealed that five key protein targets were sifted out. They are APOE (D-CS: 156.68), TNF (D-CS: 114.77), IL 10 (D-CS: 86.21), CASP 3 (D-CS: 37.17), ICAM 1 (D-CS: 37.08). b, c, d GO biological processes analysis of GF. GF’s key protein targets involved in 4 biological processes, they are the regulation of amyloid precursor protein catabolic process, regulation of membrane protein ectodomain proteolysis, regulation of nitric oxide biosynthetic process, and regulation of amyloid-beta formation.
Figure 5

The Schematic 3D representation of the molecular docking model with DRD2 and HTR2A.